PIKA Technology Platform
A Multi-Prong Approach of Immunomodulation
PIKA Technology Overview
PIKA technology consists of synthetic biologic complex that is originated from our research and synthesized based on our proprietary GMP manufacturing technology. Through TLR3, RIG-I and MDA-5 signaling pathways, PIKA molecule can induce a prompt production of interferon, cytokines, chemokines and costimulatory factors. PIKA administration facilitates antigen cross-presentation by dendritic cells and augments CD4+ T-cell, CD8+ T-cell and natural killer-cell responses. When delivered with relevant antigen-based molecules, PIKA technology can be applied to the development of a new generation of antiviral vaccines, antiviral therapeutics and anticancer therapeutics, offering a promising platform for the development of a wide variety of novel biologics to improve treatments that are currently available and address unmet medical needs.
PIKA technology is originated from our research in a class of well-defined dsRNA molecules synthesized using our proprietary technology. Endosomal dsRNA can be recognized by TLR3 while cytosolic dsRNA can be sensed by the RIG-I-like receptor family which include RIG-I and MDA-5. Through TLR3, RIG-I and MDA-5 signaling, PIKA technology can induce a prompt production of interferon, cytokines, chemokines and costimulatory factors. The antiviral and antitumor effects of interferon have been well established. Production of type I interferon upon PIKA administration facilitates antigen cross-presentation by dendritic cells and augments CD4+ T-cell, CD8+ T-cell and natural killer-cell responses, which makes PIKA-based therapeutics suitable for both antiviral and antitumor applications.